MetaVia Inc. has reported that investigational DA-1726 produced a 13.5% placebo-adjusted reduction in body weight and a 68% placebo-adjusted reduction in liver fat after approximately 16 weeks in an interim analysis from Part 3B of its first-in-human Phase 1 programme. The randomized, placebo-controlled analysis involved 15 adults with obesity receiving DA-1726 and only four receiving placebo, making the magnitude of the metabolic changes notable while leaving substantial uncertainty around how reliably the results will reproduce in larger trials.
Participants receiving the once-weekly dual GLP-1 and glucagon receptor agonist lost 11.9% of their body weight from baseline, equivalent to about 12.2 kilograms, while mean HbA1c fell from 5.79% to 5.33% despite participants entering the study without diabetes. MetaVia also reported reductions across visceral and subcutaneous adipose tissue, while five treated participants who had liver steatosis at baseline all reached liver-fat levels below the study’s 5% steatosis threshold by Day 109.
The readout has given MetaVia a clinical rationale to reposition DA-1726 increasingly toward liver-related cardiometabolic disease rather than competing solely as another obesity medicine. The company now plans a 48-week Phase 2 study involving up to 150 people with metabolic dysfunction and alcohol-associated liver disease, or MetALD, and alcohol-associated liver disease, with study initiation targeted for the second half of 2027.
The market reaction has been volatile rather than uniformly positive. MetaVia shares fell 18.7% to $1.09 on November 5 before rebounding 31.2% to $1.43 on November 6, with trading volume approaching one million shares on both days. The sharp swings reflect both enthusiasm around the clinical numbers and the risks attached to a company with a market capitalisation below $10 million, limited cash and substantial financing requirements before its planned 2027 studies can begin.
How did DA-1726 produce 13.5% placebo-adjusted weight loss after only 16 weeks?
Part 3B evaluated DA-1726 using a gradual dose-escalation strategy in otherwise healthy adults with obesity. Participants assigned to active treatment received 16 mg once weekly for four weeks, increased to 32 mg for another four weeks and then reached a target dose of 64 mg for the remaining eight weeks. The staged escalation was designed to test whether higher exposure could be reached while managing the gastrointestinal adverse effects commonly associated with incretin-based medicines.
The 15 actively treated participants entered with mean body weight of 98.6 kilograms. By Day 109, mean weight had declined by 12.19 kilograms, or 11.9% from baseline, while the placebo-adjusted reduction was 13.5% and met the company’s reported threshold for statistical significance. Waist circumference also declined by 9.6 centimetres from baseline, with a 9.1% placebo-adjusted reduction.
Those numbers will inevitably attract comparison with established and emerging obesity drugs, but direct comparisons would be unreliable. DA-1726 has been tested in a very small Phase 1 cohort over roughly four months, whereas leading obesity medicines have generally been evaluated in much larger Phase 3 populations over substantially longer treatment periods with different eligibility criteria and statistical methods.
The more important question at this stage is therefore whether the magnitude of weight loss persists as the population expands. Full Part 3A and Part 3B results are expected in the first quarter of 2027, providing a more complete assessment before MetaVia commits to later-stage development.
Why could the 68% liver-fat reduction matter more than the obesity headline?
MetaVia increasingly views DA-1726 as a potential liver-focused cardiometabolic therapy because its dual mechanism combines GLP-1 receptor activation with glucagon receptor activation. GLP-1 signalling can reduce appetite and improve glucose control, while glucagon receptor activation may increase energy expenditure and influence lipid metabolism, creating a theoretical rationale for reducing both overall weight and fat accumulation in the liver.
The MRI substudy included 12 DA-1726 recipients and four placebo participants. Mean liver fat was 5.2% in the active group at baseline compared with 8.0% in the placebo group, and MetaVia reported a 68% placebo-adjusted reduction by Day 109. The absolute treatment difference in MRI-measured liver fat was 6.4 percentage points.
The denominator behind the most striking liver claim is particularly important. Only five DA-1726-treated participants began the study with liver steatosis, defined as MRI proton density fat fraction of at least 5%. All five fell below 5% by Day 109, with their mean liver fat declining from 8.3% to 3.0%.
That result provides a useful signal but is far too small to establish effectiveness in people with clinically significant liver disease. The trial enrolled adults with obesity rather than a population selected for MetALD, alcohol-associated liver disease or advanced fibrosis, and it did not use liver biopsy to measure inflammation or fibrosis.
The placebo-adjusted 68% figure also needs to be understood in context because liver fat increased by 40.4% from baseline in the four-person placebo group. With only four controls, movement in one or two participants can materially influence the placebo-adjusted calculation, making larger randomized data essential before the effect size can be considered stable.
Why is MetaVia shifting DA-1726 toward MetALD and alcohol-associated liver disease?
The latest results give MetaVia an opportunity to pursue a market where weight loss alone is not the primary objective. MetALD describes steatotic liver disease occurring in people who have cardiometabolic risk factors alongside alcohol consumption above defined thresholds, placing the condition between predominantly metabolic liver disease and predominantly alcohol-associated disease.
MetaVia estimates that approximately 10.7 million adults in the United States have MetALD. That estimate is a company assessment rather than a projection of realistically obtainable patients or future revenue, but it illustrates why management sees liver disease as a potentially attractive development path for a small biotechnology company unable to compete commercially with large pharmaceutical companies across the entire obesity market.
The planned Phase 2 study is expected to run for 48 weeks and enroll as many as 150 patients with MetALD and alcohol-associated liver disease. MetaVia currently describes the trial as non-biopsy based, meaning imaging, biochemical and metabolic measures are expected to play an important role rather than serial histological assessment.
That design could allow the company to determine whether the liver-fat signal seen in Phase 1 persists in patients who actually have liver disease. It will not automatically establish an effect on fibrosis, hepatic decompensation or other clinical outcomes, so later development could require additional evidence depending on the regulatory strategy and indication ultimately pursued.
Does the HbA1c result suggest DA-1726 is doing more than causing weight loss?
Participants in Part 3B did not have diabetes at entry, yet mean HbA1c declined from 5.79% to 5.33% after treatment with DA-1726. The 0.44 percentage-point reduction from baseline was statistically significant, while the placebo-adjusted difference was 0.24 percentage points.
Every DA-1726 recipient with a Day 109 HbA1c measurement recorded a decline of between 0.3 and 0.8 percentage points. That consistency supports a metabolic effect beyond simple scale weight, although the study was not designed to demonstrate efficacy in type 2 diabetes and the participants began with glucose measures largely outside the diabetic range.
The combined reduction in body weight, HbA1c and liver fat is one reason MetaVia sees the programme as relevant to MetALD, where excess adiposity, insulin resistance and hepatic steatosis can overlap. Larger studies will be needed to establish whether those effects remain linked and whether they translate into improvements in clinically relevant liver disease measures.
The data should therefore be viewed as hypothesis-generating for liver disease rather than evidence that DA-1726 has already demonstrated benefit in MetALD. No participant in this Phase 1 cohort was enrolled specifically because they had MetALD or alcohol-associated liver disease.
Did DA-1726 really preserve lean mass during rapid weight loss?
MetaVia has highlighted relative preservation of lean tissue as another potentially differentiated feature. MRI analysis showed placebo-adjusted reductions of 22% in visceral adipose tissue, 19% in abdominal subcutaneous adipose tissue and 19% in total adipose tissue after approximately 16 weeks.
Lean tissue was not unchanged. Total lean tissue was 8% lower versus placebo and thigh muscle volume was 9% lower versus placebo, with both differences statistically significant. The company’s description of relative preservation refers to the fact that the proportional reductions in lean tissue and muscle were smaller than those observed in the measured fat compartments.
That distinction matters because preservation of muscle during pharmacological weight loss has become an increasingly important research question as highly effective obesity drugs produce double-digit percentage reductions in body weight. Losing less lean tissue relative to fat may ultimately be beneficial, but the current analysis does not demonstrate preserved muscle function, strength or physical performance.
The MRI substudy is also extremely small, involving 12 actively treated participants and four controls. Confirmation in larger cohorts with standardized measures of body composition and functional outcomes will be necessary before lean-mass preservation can become a credible competitive claim for DA-1726.
What does the safety profile reveal about pushing DA-1726 to 64 mg?
Gastrointestinal adverse events were common despite the gradual escalation schedule. Nine of the 15 DA-1726-treated participants reported at least one gastrointestinal event, including vomiting in seven participants, nausea in two, diarrhea in two, dyspepsia in two, constipation in one and abdominal pain in one.
Vomiting therefore occurred in 46.7% of actively treated participants. One participant experienced severe vomiting classified as a serious adverse event and considered possibly related to DA-1726, although the participant recovered. No gastrointestinal adverse event led to study discontinuation.
MetaVia also reported that no new gastrointestinal adverse events occurred after Week 9 through the Day 109 interim assessment. That pattern could indicate that tolerability improved once participants completed dose escalation and remained on the target dose, but the cohort is too small to define the frequency of severe or uncommon adverse events reliably.
Safety will become particularly important if DA-1726 moves into people with established liver disease, who may differ substantially from otherwise healthy adults with obesity. A 48-week Phase 2 trial should provide considerably more information about persistence, treatment discontinuation, dose modification and adverse-event burden.
How does DA-1726’s GLP-1 and glucagon mechanism differentiate it from conventional GLP-1 drugs?
DA-1726 is an oxyntomodulin analogue engineered to activate both the GLP-1 receptor and glucagon receptor, with MetaVia describing a 3:1 GLP-1-to-glucagon receptor potency ratio. The objective is to combine appetite suppression and glucose regulation from GLP-1 activity with increased energy expenditure and lipid mobilisation associated with glucagon signalling.
The strategy places DA-1726 within a broader industry effort to move beyond single-receptor GLP-1 medicines. Several companies are developing dual and triple agonists that add GIP or glucagon activity in an attempt to increase weight loss, alter energy expenditure or address metabolic complications beyond obesity itself.
MetaVia has also generated preclinical distribution data showing the highest exposure to DA-1726-derived radioactivity in adipose tissue, with substantial exposure in the liver. Those animal findings provide mechanistic support for the company’s liver-focused development thesis but cannot demonstrate that tissue distribution in animals will translate into superior clinical outcomes in humans.
The 68% liver-fat result is therefore more useful than the preclinical distribution work because it provides direct human evidence of a liver-related effect. Even so, the clinical result is currently limited to a small MRI substudy and should not be treated as evidence that DA-1726 has established a therapeutic advantage over other incretin or glucagon-containing medicines.
Why is MetaVia’s balance sheet almost as important as the clinical data?
MetaVia had $12.6 million in cash and cash equivalents at June 30, 2026 and no debt, according to its latest disclosed financial position. The company’s November presentation indicated that its existing resources were expected to fund the current operating plan into the first quarter of 2027.
That runway is considerably shorter than the development timetable MetaVia has outlined. The company targets a Phase 2a study of vanoglipel with resmetirom during the first half of 2027 and the DA-1726 Phase 2 MetALD and alcohol-associated liver disease trial during the second half, while management explicitly states that its 2027 clinical programmes are contingent on additional financing.
MetaVia therefore faces a familiar small-biotechnology tension. Positive clinical data can increase strategic and financing options, but progressing a 150-patient, 48-week trial requires capital far beyond the cost of the current 19-person interim analysis.
Shareholders also need to consider the company’s capital structure. MetaVia reported approximately 6.58 million common shares outstanding at June 30 but roughly 15.77 million shares on a fully diluted basis when warrants, restricted stock units and other potential equity are included. Several million warrants carry exercise prices well above the current share price, so future capital raising rather than immediate warrant exercise may remain the more relevant dilution question unless the stock appreciates substantially.
Why did MTVA stock jump 31% one day after initially falling on the same data?
MetaVia shares closed November 5 at $1.09, down 18.7%, despite publication of the interim results. The stock then reversed direction on November 6, gaining 31.2% to $1.43 as approximately 969,000 shares traded.
The two-session move is more informative than looking only at the 31% rebound. Compared with the November 4 close of $1.34, the November 6 finish represented a gain of only about 6.7%, meaning the market initially reacted negatively before renewed buying pushed the stock moderately above its pre-readout level.
The trading volume nevertheless shows elevated investor attention. MetaVia’s market capitalisation remained around $9 million after the rebound, making even relatively modest changes in investor demand capable of producing outsized percentage moves.
The stock also remains dramatically below its 52-week high above $13, illustrating how much risk investors have already assigned to financing, clinical development and execution. The DA-1726 results provide a new catalyst but do not remove the structural vulnerabilities associated with an early-stage company that has no commercial revenue and needs additional capital.
What will determine whether the DA-1726 signal survives beyond Phase 1?
The first checkpoint is the complete Part 3A and Part 3B dataset expected during the first quarter of 2027. Full data should clarify the 48 mg and 64 mg dose profiles, adverse events, weight trajectory and whether the liver and body-composition findings remain consistent when all participants and assessments are included.
The more consequential test will come from the planned 48-week Phase 2 study in MetALD and alcohol-associated liver disease. A larger population with actual liver disease can determine whether DA-1726 reproducibly reduces liver fat and metabolic risk factors over a longer period while maintaining acceptable tolerability.
Financing is the other near-term dependency. MetaVia has acknowledged that its planned 2027 programmes require additional capital, making fundraising, partnership activity or other strategic funding almost inseparable from the clinical development timeline.
DA-1726 has produced an unusually strong-looking early numerical signal, particularly the combination of 11.9% weight loss from baseline, lower HbA1c and sharply reduced MRI liver fat after only 16 weeks. The next stage must establish whether those results reflect a genuinely differentiated drug or the volatility that can arise when a promising therapy is tested in 15 treated patients against four controls. Until larger randomized data arrive, both interpretations remain possible.
